Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs
Authors' conclusion
The incidence of overall cancer and CVD were not increased in patients with SPRA treated with JAKi/biologics and was relatively lower than csDMARD only users
Study context
- Population
- Patients with new-onset seropositive rheumatoid arthritis (RA) (seropositive RA (SPRA)) during 2010–2020 in the national healthcare database101,816 (cancers) and 96,220 (CVD) analysed
- Exposure
- JAKi/biologics vs conventional synthetic disease-modifying anti-rheumatic drug (csDMARDs) only
- Outcome
- Overall and site-specific cancers, and CVD outcomes (DVT, PE, composite cardiovascular events)
Methodological detailsnational healthcare database, time-dependent Cox analyses
- National healthcare database
- Time-dependent Cox analyses
Main finding
As reported in the abstract
Each group vs csDMARDs onlyEstimate (95% CI)
JAKi/biologics
IRR (overall cancers) 0.88(0.86–0.89)
JAKi/biologics
IRR (CVDs) 0.91(0.90–0.92)
Observational data: associations, not effects.
Further findings
Site-specific cancers
- Lung, liver, prostate and skin cancers more frequent in JAKi/biologics users
JAKi vs other biologics and csDMARDs
- JAKi did not confer a greater risk of overall CVDs and cancers compared with other biologics and csDMARDs
Adjusted Cox analyses
- JAKi/biologics usage was not accounted for overall cancers and CVDs
Original publication
Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs. Clin Exp Rheumatol. Published 18 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →